Narrative review examines how immune checkpoint inhibitors achieving 60-100% pathological complete response rates in MSI-H/dMMR CRC are challenging traditional recommendations for extensive prophylactic surgery in Lynch syndrome patients. (European Journal of Surgical Oncology)
Immunotherapy transforms surgical decisions in Lynch syndrome CRC
The CRC Digest